Atlantic Health System Cancer Care will continue its tradition of world-class medical education by hosting its 2021 Annual Review in Oncology Virtual Symposium. The symposium, held via Microsoft Teams with free registration, will take place Saturday, June 26, 2021, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the nation’s leading cancer centers will summarize the latest advances in six areas of oncology, as presented at the just-completed ASCO conference—the world’s premiere meeting for cancer care professionals and researchers.
Tag: ASCO 2021
New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Roswell Park Researchers Gear Up for ASCO 2021 Annual Meeting
At the American Society of Clinical Oncology 2021 virtual Annual Meeting, Roswell Park teams will share data and insights on topics ranging from reducing use of opioids to an analysis of trends in response to cancer treatment among patients of different races.
Immunotherapy drug delays recurrence in kidney cancer patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
Moffitt Cancer Center Experts to Present New Clinical Research Data
Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two clinical science symposia. The virtual meeting is June 4-8.
“Electronic Nose” Accurately Sniffs Out Hard-to-Detect Cancers
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy.
Survival benefits of immunotherapy combination persist for more than six years in patients with advanced melanoma
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
Combination therapy achieves high rates of response for patients with acute lymphoblastic leukemia
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.
Immunotherapy combination shows benefit for patients with advanced melanoma, phase 3 trial shows
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Extensive, Wide-Ranging New Cancer Research Data at the 2021 ASCO Annual Meeting
Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8.